http://pharmabiz.com/NewsDetails.aspx?aid=153440&sid=2 Web23 sep. 2024 · About ION449 ION449 (AZD8233) dosed once monthly via subcutaneous administration, is an investigational medicine that uses Ionis' advanced LI gand- C …
PCSK9 pipeline shows signs of saturation Evaluate
Web5 apr. 2024 · Self-administered subcutaneous monthly dose with a potential best-in-class efficacy profile . LONDON, UK I April 04, 2024 I Positive results from the ETESIAN Phase IIb trial showed AZD8233 (an investigational antisense oligonucleotide [ASO], also known as ION449) met the primary endpoint at 50 mg with 73% (95% confidence interval [CI]: … Web1 mrt. 2024 · More recently, positive results from the ETESIAN Phase IIb trial, investigating a first chemically modified, GalNAclinked 16-mer ASO to target PCSK9 gene expression in the nucleus (AZD8233 also ... china airlines reviews tripadvisor
AstraZeneca, Ionis’ AZD8233 reduces LDL-C levels in Phase 2b …
Web5 apr. 2024 · AZD8233 is a novel, investigational ASO therapy designed to reduce blood cholesterol levels in patients with hypercholesterolemia, or elevated LDL-C levels in the blood. The drug works by inhibiting PCSK9 expression to increase LDL receptor levels, which results in lower LDL-C levels, and cuts the risk of developing coronary heart disease. AZD8233 (also known as ION 449), dosed once monthly via subcutaneous administration, is a novel, investigational ASO therapy designed to reduce blood cholesterol levels in patients with hypercholesterolemia by inhibiting PCSK9 expression in the nucleus. Web23 sep. 2024 · Ionis Pharmaceuticals, Inc. IONS announced top-line data from the phase IIb SOLANO study, which evaluated its PCSK9 antisense medicine, ION449 (AZD8233), for the treatment of patients with... grady white new models